Browse by UCL people
Group by: Type | Date
Number of items: 160.
Article
(2021)
The contemporary role of MRI in the monitoring and management of people with multiple sclerosis in the UK.
Multiple Sclerosis and Related Disorders
, 55
, Article 103190. 10.1016/j.msard.2021.103190.
|
|
Affinito, Giuseppina;
Moccia, Marcello;
Lanzillo, Roberta;
Marrie, Ruth Ann;
Chataway, Jeremy;
Brescia Morra, Vincenzo;
Palladino, Raffaele;
(2025)
Neural networks to estimate multiple sclerosis disability and predict progression using routinely collected healthcare data.
Multiple Sclerosis Journal
10.1177/13524585251347513.
(In press).
|
 |
|
Al-Araji, Sarmad;
Moccia, Marcello;
Jha, Ashwani;
Zhang, Le;
Eshaghi, Arman;
Kanber, Baris;
Bianchi, Alessia;
... Ciccarelli, Olga; + view all
(2025)
Effectiveness of Disease-Modifying Therapies in
Patients With Late-Onset Relapsing-Remitting Multiple
Sclerosis.
Neurology
, 105
(4)
, Article e213967. 10.1212/WNL.000000000021396.
|
 |
|
Alexander, Sarah;
Braisher, Marie;
Tur, Carmen;
Chataway, Jeremy;
(2022)
The mSteps pilot study: Analysis of the distance walked using a novel smartphone application in multiple sclerosis.
Multiple Sclerosis Journal
, 28
(14)
pp. 2285-2293.
10.1177/13524585221124043.
|
          |
|
Alexander, S;
Peryer, G;
Gray, E;
Barkhof, F;
Chataway, J;
(2020)
Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review.
Multiple Sclerosis Journal
10.1177/1352458520946005.
(In press).
|
|
|
Arun, Tarunya;
Petheram, Kate;
Tallantyre, Emma;
Ford, Helen;
Chataway, Jeremy;
Mac Dougall, Niall;
Doshi, Anisha;
... Dobson, Ruth; + view all
(2024)
Assessing the landscape and charting paths: UK neurology trainees' opinions on neuroinflammation subspecialty.
Multiple Sclerosis and Related Disorders
, 92
, Article 106144. 10.1016/j.msard.2024.106144.
|
|
Blackstone, James;
Williams, Thomas;
Nicholas, Jennifer M;
Bordea, Ekaterina;
De Angelis, Floriana;
Bianchi, Alessia;
Calvi, Alberto;
... Chataway, Jeremy; + view all
(2024)
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.
BMJ Open
, 14
(9)
, Article e086414. 10.1136/bmjopen-2024-086414.
|
|
Bonati, LH;
Gregson, J;
Dobson, J;
McCabe, DJH;
Nederkoorn, PJ;
van der Worp, HB;
de Borst, GJ;
... International Carotid Stenting Study investigators, .; + view all
(2018)
Restenosis and risk of stroke after stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): secondary analysis of a randomised trial.
The Lancet Neurology
, 17
(7)
pp. 587-596.
10.1016/S1474-4422(18)30195-9.
|
|
Brownlee, W;
Chataway, J;
(2017)
Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome.
Multiple Sclerosis Journal
, 23
(6)
pp. 876-877.
10.1177/1352458517693440.
|
|
Calvi, Alberto;
Carrasco, Ferran Prados;
Tur, Carmen;
Chard, Declan T;
Stutters, Jonathan;
De Angelis, Floriana;
John, Nevin;
... MSSMART Investigators, .; + view all
(2022)
Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis.
Neurology
, 98
(17)
e1783-e1793.
10.1212/WNL.0000000000200144.
|
|
Campbell Cree, BA;
Arnold, DL;
Chataway, J;
Chitnis, T;
Fox, RJ;
Ramajo, AP;
Murphy, N;
(2021)
Secondary Progressive Multiple Sclerosis: New Insights.
Neurology
10.1212/WNL.0000000000012323.
(In press).
|
|
Chan, D;
Binks, S;
Nicholas, JM;
Frost, C;
Cardoso, MJ;
Ourselin, S;
Wilkie, D;
... Chataway, J; + view all
(2017)
Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.
The Lancet Neurology
, 16
(8)
pp. 591-600.
10.1016/S1474-4422(17)30113-8.
|
|
Chard, D;
Trip, A;
Chataway, J;
(2016)
New oral drugs for the treatment of multiple sclerosis.
British Journal of Hospital Medicine
, 77
(9)
pp. 502-503.
10.12968/hmed.2016.77.9.502.
|
|
Chataway, J;
Murphy, N;
Khurana, V;
Schofield, H;
Findlay, J;
Adlard, N;
(2021)
Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities.
Current Medical Research and Opinion
, 37
(6)
pp. 995-1004.
10.1080/03007995.2021.1904860.
|
|
Chataway, Jeremy;
Wade, Charles;
Murphy, Elaine;
Lynch, David S;
(2024)
An alternative therapeutic approach to haematopoetic stem cell transplantation in early cerebral adrenoleukodystrophy.
Brain
, 147
(10)
pp. 3271-3273.
10.1093/brain/awae261.
|
|
Chataway, Jeremy;
Williams, Thomas;
Blackstone, James;
John, Nevin;
Braisher, Marie;
De Angelis, Floriana;
Bianchi, Alessia;
... MS-STAT2 Investigators; + view all
(2025)
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.
The Lancet
, 406
(10512)
pp. 1611-1624.
10.1016/S0140-6736(25)01039-6.
|
|
Chataway, Jeremy;
Williams, Thomas;
Li, Vivien;
Marrie, Ruth Ann;
Ontaneda, Daniel;
Fox, Robert J;
(2024)
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges.
The Lancet Neurology
, 23
(3)
pp. 277-301.
10.1016/S1474-4422(24)00027-9.
|
|
Chataway, J;
(2020)
Distribution of plaques in the cerebrum in multiple sclerosis.
Journal of Neurology, Neurosurgery & Psychiatry
10.1136/jnnp-2019-322431.
(In press).
|
|
|
Chataway, J;
(2018)
Tackling progression in multiple sclerosis.
[Editorial comment].
The Lancet Neurology
, 17
(6)
pp. 489-491.
10.1016/S1474-4422(18)30158-3.
|
|
Chataway, J;
(2018)
Evolving diagnostic criteria for multiple sclerosis.
The Lancet Neurology
, 17
(2)
p. 118.
10.1016/S1474-4422(17)30463-5.
|
|
Chataway, J;
(2017)
Treating clinically isolated syndrome: the lone game.
Journal of Neurology, Neurosurgery and Psychiatry
, 88
(4)
, Article 284. 10.1136/jnnp-2016-315115.
|
|
Chataway, J;
(2017)
Treating clinically isolated syndrome: the long game.
Journal of Neurology, Neurosurgery & Psychiatry
, 88
(4)
, Article 284. 10.1136/jnnp-2016-315115.
|
|
|
Chataway, J;
(2016)
Biotin in progressive multiple sclerosis – a new lead?
Multiple Sclerosis Journal
, 22
(13)
pp. 1640-1641.
10.1177/1352458516676387.
|
|
Chataway, J;
(2016)
Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - YES.
Multiple Sclerosis Journal
, 23
(4)
pp. 505-506.
10.1177/1352458516671821.
|
|
|
Chataway, J;
(2016)
NICE guideline practical summary: multiple sclerosis.
BMJ Learning
|
|
Chataway, J;
De Angelis, F;
Connick, P;
Parker, RA;
Plantone, D;
Doshi, A;
John, N;
... MS-SMART Investigators; + view all
(2020)
Efficacy of three neuroprotective drugs in secondary
progressive multiple sclerosis (MS-SMART): a phase 2b,
multiarm, double-blind, randomised placebo-controlled trial.
The Lancet Neurology
10.1016/S1474-4422(19)30485-5.
(In press).
|
|
|
Chataway, J;
Friede, T;
(2016)
The N-MOmentum trial: Building momentum to advance trial methodology in a rare disease.
Multiple Sclerosis Journal
, 22
(7)
pp. 852-853.
10.1177/1352458516643399.
|
|
Chataway, J;
Martin, K;
Barrell, K;
Sharrack, B;
Stolt, P;
Wraith, D;
for the ATX-MS 1467 Study Group;
(2018)
Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis.
Neurology
, 90
(11)
, Article e962. 10.1212/WNL.0000000000005118.
|
|
Chataway, J;
Schuerer, N;
Alsanousi, A;
Chan, D;
MacManus, D;
Hunter, K;
Anderson, V;
... Nicholas, R; + view all
(2014)
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Lancet
, 383
(9936)
pp. 2213-2221.
10.1016/S0140-6736(13)62242-4.
|
|
|
Chataway, J;
Weir, CJ;
Fox, RJ;
(2019)
The FLUOX-PMS trial: Underestimating the challenge in progressive multiple sclerosis trials.
Multiple Sclerosis Journal
, 25
(13)
1697 -1699.
10.1177/1352458519856985.
|
|
|
Chiaravalloti, Nancy D;
DeLuca, John;
Salter, Amber;
Amato, Maria Pia;
Brichetto, Giampaolo;
Chataway, Jeremy;
Dalgas, Ulrik;
... Feinstein, Anthony; + view all
(2022)
The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis.
Multiple Sclerosis Journal
10.1177/13524585221088190.
(In press).
|
|
Chiaravalloti, ND;
Amato, MP;
Brichetto, G;
Chataway, J;
Dalgas, U;
DeLuca, J;
Meza, C;
... Feinstein, A; + view all
(2020)
The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosis.
Journal of Neurology
, 268
(5)
pp. 1598-1607.
10.1007/s00415-020-10160-7.
|
|
|
Colato, Elisa;
Stutters, Jonathan;
Narayanan, Sridar;
Arnold, Douglas L;
Chataway, Jeremy;
Wheeler-Kingshott, Claudia AM Gandini;
Barkhof, Frederik;
... Chard, Declan T; + view all
(2024)
Longitudinal network-based brain grey matter MRI measures are clinically relevant and sensitive to treatment effects in multiple sclerosis.
Brain Communications
, 6
(4)
, Article fcae234. 10.1093/braincomms/fcae234.
|
|
Connick, P;
De Angelis, F;
Parker, RA;
Plantone, D;
Doshi, A;
John, N;
Stutters, J;
... UK Multiple Sclerosis Society Clinical Trials Network; + view all
(2018)
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.
BMJ Open
, 8
, Article e021944. 10.1136/bmjopen-2018-021944.
|
|
|
Connolly, L;
Chatfield, S;
Freeman, J;
Salter, A;
Amato, MP;
Brichetto, G;
Chataway, J;
... Feinstein, A; + view all
(2024)
Associations between fatigue impact and physical and neurobehavioural factors: An exploration in people with progressive multiple sclerosis.
Multiple Sclerosis and Related Disorders
, 90
, Article 105798. 10.1016/j.msard.2024.105798.
|
|
Dangond, F;
Donnelly, A;
Hohlfeld, R;
Lubetzki, C;
Kohlhaas, S;
Leocani, L;
Ciccarelli, O;
... Salvetti, M; + view all
(2021)
Facing the urgency of therapies for progressive MS — a Progressive MS Alliance proposal.
Nature Reviews Neurology
, 17
pp. 185-192.
10.1038/s41582-020-00446-9.
|
   |
|
De Angelis, Floriana;
Ammoscato, Francesca;
Parker, Richard A;
Plantone, Domenico;
Doshi, Anisha;
John, Nevin A;
Williams, Thomas;
... MS-SMART Trial, Investigators; + view all
(2025)
Neurofilament heavy chain in secondary progressive multiple sclerosis.
Multiple Sclerosis Journal
10.1177/13524585241311212.
(In press).
|
|
De Angelis, Floriana;
Cameron, James R;
Eshaghi, Arman;
Parker, Richard;
Connick, Peter;
Stutters, Jonathan;
Plantone, Domenico;
... MS-SMART, Trial Investigators; + view all
(2024)
Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial.
Journal of Neurology, Neurosurgery and Psychiatry
10.1136/jnnp-2024-334801.
(In press).
|
|
De Angelis, F;
Chataway, J;
(2019)
Novel multiple sclerosis drugs in the pipeline.
Clinical Pharmacology and Therapeutics
, 105
(5)
pp. 1082-1090.
10.1002/cpt.1412.
|
|
De Angelis, F;
Connick, P;
Parker, RA;
Plantone, D;
Doshi, A;
John, N;
Stutters, J;
... Chataway, J; + view all
(2020)
Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT.
Efficacy and Mechanism Evaluation
, 7
(3)
pp. 1-72.
10.3310/eme07030.
|
|
|
De Angelis, F;
Plantone, D;
Chataway, J;
(2018)
Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview.
CNS Drugs
, 32
(6)
pp. 499-526.
10.1007/s40263-018-0538-0.
|
|
Dobson, Ruth;
Arun, Tarunya;
Varley, James;
Chataway, Jeremy;
Brownlee, Wallace;
Gallagher, Paul;
Giovannoni, Gavin;
... Coles, Alasdair; + view all
(2025)
Approach to JCV testing with natalizumab biosimilar: a UK consensus statement.
Multiple Sclerosis and Related Disorders
, 100
, Article 106541. 10.1016/j.msard.2025.106541.
(In press).
|
|
|
Doshi, Anisha;
Muhlert, Nils;
Castellazzi, Gloria;
Alahmadi, Adnan;
De Angelis, Floriana;
Prados, Ferran;
Stutters, Jon;
... Chataway, Jeremy; + view all
(2025)
Investigating the impact of different dichotomous definitions for cognitive impairment on functional connectivity in secondary progressive MS.
Multiple Sclerosis and Related Disorders
, 95
, Article 106270. 10.1016/j.msard.2025.106270.
|
|
|
Doshi, A;
Chataway, J;
(2017)
Multiple sclerosis, a treatable disease.
Clinical Medicine
, 17
(6)
pp. 530-536.
10.7861/clinmedicine.17-6-530.
|
|
Doshi, A;
Chataway, J;
(2016)
Multiple sclerosis, a treatable disease.
Clinical Medicine
, 16
(Suppl 6)
s53-s59.
10.7861/clinmedicine.16-6-s53.
|
|
Eshaghi, A;
Kievit, RA;
Prados Carrasco, F;
Sudre, C;
Nicholas, J;
Cardoso, MJ;
Chan, D;
... Ciccarelli, O; + view all
(2019)
Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis.
Proceedings of the National Academy of Sciences of The United States of America (PNAS)
, 116
(22)
10.1073/pnas.1818978116.
|
|
|
Eskyte, I;
Manzano, A;
Pepper, G;
Pavitt, S;
Ford, H;
Bekker, H;
Chataway, J;
... Potrata, B; + view all
(2019)
Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis.
Multiple Sclerosis and Related Disorders
, 27
pp. 370-377.
10.1016/j.msard.2018.11.016.
|
|
|
Feinstein, Anthony;
Amato, Maria Pia;
Brichetto, Giampaolo;
Chataway, Jeremy;
Chiaravalloti, Nancy D;
Cutter, Gary;
Dalgas, Ulrik;
... Salter, Amber; + view all
(2021)
The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience.
Journal of Neurology
, 269
(4)
pp. 1758-1763.
10.1007/s00415-021-10881-3.
|
|
Feinstein, Anthony;
Amato, Maria Pia;
Brichetto, Giampaolo;
Chataway, Jeremy;
Chiaravalloti, Nancy D;
Cutter, Gary;
Dalgas, Ulrik;
... CogEx Research Team; + view all
(2023)
Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis (CogEx): a randomised, blinded, sham-controlled trial.
The Lancet Neurology
, 22
(10)
pp. 912-924.
10.1016/S1474-4422(23)00280-6.
|
|
Feinstein, Anthony;
Amato, Maria Pia;
Brichetto, Giampaolo;
Chataway, Jeremy;
Chiaravalloti, Nancy D;
Cutter, Gary;
Dalgas, Ulrik;
... Salter, Amber; + view all
(2022)
The late onset of emotional distress in people with progressive multiple sclerosis during the Covid-19 pandemic: longitudinal findings from the CogEx study.
Journal of Neurology
, 269
pp. 6202-6210.
10.1007/s00415-022-11295-5.
|
|
Feinstein, A;
Amato, MP;
Brichetto, G;
Chataway, J;
Chiaravalloti, N;
Dalgas, U;
DeLuca, J;
... Cutter, G; + view all
(2020)
Study protocol: improving cognition in people with progressive multiple sclerosis: a multi-arm, randomized, blinded, sham-controlled trial of cognitive rehabilitation and aerobic exercise (COGEx).
BMC Neurology
, 20
, Article 204. 10.1186/s12883-020-01772-7.
|
|
|
Fitzgerald, KC;
Munger, KL;
Hartung, H-P;
Freedman, MS;
Montalbán, X;
Edan, G;
Wicklein, E-M;
... BENEFIT Study Group; + view all
(2017)
Sodium intake and multiple sclerosis activity and progression in BENEFIT.
Annals of Neurology
, 82
(1)
pp. 20-29.
10.1002/ana.24965.
|
|
|
Foltynie, Tom;
Gandhi, Sonia;
Gonzalez-Robles, Cristina;
Zeissler, Marie-Louise;
Mills, Georgia;
Barker, Roger;
Carpenter, James;
... EJS ACT-PD Consortium; + view all
(2023)
Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson's disease.
Brain
, Article awad063. 10.1093/brain/awad063.
|
|
Fox, RJ;
Chataway, J;
(2017)
Advancing trial design in progressive multiple sclerosis.
Multiple Sclerosis Journal
, 23
(12)
pp. 1573-1578.
10.1177/1352458517729768.
|
|
Gagliardi, Delia;
Wade, Charles;
Tucci, Arianna;
Houlden, Henry;
Chataway, Jeremy;
Barkhof, Frederik;
Lynch, David S;
(2025)
Analysis of GFAP variants in UK Biobank suggests underdiagnosis or incomplete penetrance of adult-onset Alexander disease.
Journal of Neurology, Neurosurgery & Psychiatry
, 96
(8)
pp. 728-735.
10.1136/jnnp-2024-335089.
|
|
|
Garjani, Afagh;
Liu, Brandon Jun-Yu;
Allen, Christopher Martin;
Gunzler, Douglas David;
Gerry, Stephen William;
Planchon, Sarah Marie;
das Nair, Roshan;
... Evangelou, Nikos; + view all
(2022)
Decentralised clinical trials in multiple sclerosis research.
Multiple Sclerosis Journal
, 29
(3)
pp. 314-486.
10.1177/13524585221100401.
|
|
Goodwin, Elizabeth;
Heather, Amy;
Morrish, Nia;
Freeman, Jenny;
Boddy, Kate;
Thomas, Sarah;
Chataway, Jeremy;
... Hawton, Annie; + view all
(2025)
Comparative Responsiveness of Preference-Based Health-Related Quality of Life, Social Care and Wellbeing Measures in the Context of Multiple Sclerosis.
Value Health
10.1016/j.jval.2025.09.3063.
(In press).
|
|
|
Gray, Emma;
Amjad, Anneesa;
Robertson, Jenny;
Beveridge, Judy;
Scott, Susan;
Peryer, Guy;
Braisher, Marie;
... Chataway, Jeremy; + view all
(2023)
Enhancing involvement of people with multiple sclerosis in clinical trial design.
Multiple Sclerosis Journal
, 29
(9)
pp. 1162-1173.
10.1177/13524585231189678.
|
|
Halliday, A;
Bulbulia, R;
Bonati, LH;
Chester, J;
Cradduck-Bamford, A;
Peto, R;
Pan, H;
(2021)
Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy.
The Lancet
, 398
(10305)
pp. 1065-1073.
10.1016/S0140-6736(21)01910-3.
|
|
|
Hawton, A;
Goodwin, E;
Boddy, K;
Freeman, J;
Thomas, S;
Chataway, J;
Green, C;
(2020)
Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years.
Multiple Sclerosis Journal
10.1177/1352458520954172.
(In press).
|
|
|
Jandric, D;
Doshi, A;
Scott, R;
Paling, D;
Rog, D;
Chataway, J;
Schoonheim, M;
... Muhlert, N; + view all
(2022)
A Systematic Review of Resting-State Functional MRI Connectivity Changes and Cognitive Impairment in Multiple Sclerosis.
Brain Connectivity
, 12
(2)
pp. 112-133.
10.1089/brain.2021.0104.
|
|
John, NA;
Li, Y;
De Angelis, F;
Stutters, J;
Prados, F;
Doshi, A;
Calvi, A;
... Chataway, J; + view all
(2025)
Vascular risk factors are associated with grey matter atrophy in secondary progressive multiple sclerosis.
European Journal of Neurology
, 32
(1)
, Article e16586. 10.1111/ene.16586.
|
|
John, Nevin;
Li, Yingtong;
De Angelis, Floriana;
Stutters, Jonathan;
Carrasco, Ferran Prados;
Eshaghi, Arman;
Doshi, Anisha;
... Chataway, Jeremy; + view all
(2024)
Brain reserve and physical disability in secondary progressive multiple sclerosis.
BMJ Neurology Open
, 6
(2)
, Article e000670. 10.1136/bmjno-2024-000670.
|
|
|
John, N;
Carroll, A;
Brownlee, WJ;
Chataway, J;
(2019)
Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis.
[Letter].
Journal of Neurology, Neurosurgery & Psychiatry
10.1136/jnnp-2019-320687.
(In press).
|
|
|
Karunaratne, K;
Ahrabian, D;
Monoghan, B;
Campion, T;
Yousry, T;
Lunn, MP;
Zandi, MS;
... Chataway, J; + view all
(2021)
Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis.
BMJ Open Neurology
, 3
(1)
, Article e000096. 10.1136/bmjno-2020-000096.
|
|
|
Lakshmanan, R;
Adams, ME;
Lynch, DS;
Kinsella, JA;
Phadke, R;
Schott, JM;
Murphy, E;
... Davagnanam, I; + view all
(2017)
Redefining the phenotype of ALSP and AARS2 mutation-related leukodystrophy.
Neurology Genetics
, 3
(2)
, Article e135. 10.1212/NXG.0000000000000135.
|
|
Lanzillo, R;
Moccia, M;
Russo, CV;
Carotenuto, A;
Nozzolillo, A;
Petruzzo, M;
Palladino, R;
... Brescia Morra, V; + view all
(2019)
Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin.
Multiple Sclerosis and Related Disorders
, 28
pp. 193-196.
10.1016/j.msard.2018.12.042.
|
|
Leckey, Claire A;
Coulton, John B;
Giovannucci, Tatiana A;
He, Yingxin;
Aslanyan, Aram;
Laban, Rhiannon;
Heslegrave, Amanda;
... Paterson, Ross W; + view all
(2024)
Cerebrospinal fluid neurofilament light chain profiling and quantitation in neurological diseases.
Brain Communications
, 6
(3)
, Article fcae132. 10.1093/braincomms/fcae132.
|
|
|
Lerede, A;
Rodgers, J;
Middleton, RM;
Hampshire, A;
Nicholas, R;
Coles, A;
Chataway, J;
... Ford, DV; + view all
(2023)
Patient-reported outcomes in multiple sclerosis: a prospective registry cohort study.
Brain Communications
, 5
(4)
, Article fcad199. 10.1093/braincomms/fcad199.
(In press).
|
|
Lewin, A;
Hamilton, S;
Witkover, A;
Langford, P;
Nicholas, R;
Chataway, J;
Bangham, CRM;
(2016)
Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis.
Wellcome Open Research
, 1
, Article 10. 10.12688/wellcomeopenres.9967.2.
|
|
|
Lewin, A;
Hamilton, S;
Witkover, A;
Langford, P;
Nicholas, R;
Chataway, J;
Bangham, CRM;
(2016)
Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis.
Wellcome Open Research
, 1
, Article 10. 10.12688/wellcomeopenres.9967.1.
|
|
|
Li, Vivien;
Leurent, Baptiste;
Barkhof, Frederik;
Braisher, Marie;
Cafferty, Fay;
Ciccarelli, Olga;
Eshaghi, Arman;
... Chataway, Jeremy; + view all
(2022)
Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis.
Neurology
10.1212/WNL.0000000000200604.
(In press).
|
|
|
Li, V;
Barker, N;
Curtis, C;
Porter, B;
Panicker, JN;
Chataway, J;
Pakzad, M;
(2020)
The prevention and management of hospital admissions for urinary tract infection in patients with multiple sclerosis.
Multiple Sclerosis and Related Disorders
, 45
, Article 102432. 10.1016/j.msard.2020.102432.
|
|
Li, V;
Panicker, JN;
Haslam, C;
Chataway, J;
(2020)
Use of a symptom-based questionnaire to screen for the presence of significant voiding dysfunction in patients with multiple sclerosis and lower urinary tract symptoms: a pilot study.
Journal of Neurology
10.1007/s00415-020-10068-2.
|
|
Lynch, DS;
Jaunmuktane, Z;
Sheerin, UM;
Phadke, R;
Brandner, S;
Milonas, I;
Dean, A;
... Houlden, H; + view all
(2016)
Hereditary leukoencephalopathy with axonal spheroids: a spectrum of phenotypes from CNS vasculitis to parkinsonism in an adult onset leukodystrophy series.
Journal of Neurology, Neurosurgery and Psychiatry
, 87
(5)
pp. 512-519.
10.1136/jnnp-2015-310788.
|
|
|
Lynch, DS;
Rodrigues Brandão de Paiva, A;
Zhang, WJ;
Bugiardini, E;
Freua, F;
Tavares Lucato, L;
Macedo-Souza, LI;
... Houlden, H; + view all
(2017)
Clinical and genetic characterization of leukoencephalopathies in adults.
Brain
, 140
(5)
pp. 1204-1211.
10.1093/brain/awx045.
|
|
Lynch, DS;
Wade, C;
Paiva, ARBD;
John, N;
Kinsella, JA;
Merwick, Á;
Ahmed, RM;
... Chataway, J; + view all
(2019)
Practical approach to the diagnosis of adult-onset leukodystrophies: an updated guide in the genomic era.
Journal of Neurology, Neurosurgery & Psychiatry
, 90
(5)
pp. 543-554.
10.1136/jnnp-2018-319481.
|
|
Lynch, DS;
Zhang, WJ;
Lakshmanan, R;
Kinsella, JA;
Uzun, GA;
Karbay, M;
Tufekcioglu, Z;
... Houlden, H; + view all
(2016)
Analysis of Mutations in AARS2 in a Series of CSF1R-Negative Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia.
JAMA Neurology
, 73
(12)
pp. 1433-1439.
10.1001/jamaneurol.2016.2229.
|
|
Manzano, A;
Eskyte, I;
Ford, HL;
Pavitt, SH;
Potrata, B;
Schmierer, K;
Chataway, J;
... Bekker, HL; + view all
(2020)
Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
Multiple Sclerosis and Related Disorders
, 46
, Article 102507. 10.1016/j.msard.2020.102507.
|
|
Manzano, A;
Eskytė, I;
Ford, HL;
Bekker, HL;
Potrata, B;
Chataway, J;
Schmierer, K;
... Pavitt, SH; + view all
(2020)
Impact of communication on first treatment decisions in people with relapsing-remitting multiple sclerosis.
Patient Education and Counseling
, 103
(12)
pp. 2540-2547.
10.1016/j.pec.2020.05.014.
|
|
Marrie, Ruth Ann;
Chataway, Jeremy;
Bierer, Barbara E;
Finlayson, Marcia;
Martinez-Lapiscina, Elena H;
Panagoulias, Jennifer;
Sormani, Maria Pia;
... Amezcua, Lilyana; + view all
(2023)
Enhancing diversity of clinical trial populations in multiple sclerosis.
Multiple Sclerosis Journal
, 29
(9)
pp. 1174-1185.
10.1177/13524585231189677.
|
|
Marrie, Ruth Ann;
Sormani, Maria Pia;
Mangion, Sean Apap;
Bovis, Francesca;
Cheung, Winson Y;
Cutter, Gary R;
Feys, Peter;
... Chataway, Jeremy; + view all
(2023)
Improving the efficiency of clinical trials in multiple sclerosis.
Multiple Sclerosis Journal
, 29
(9)
pp. 1136-1148.
10.1177/13524585231189671.
|
|
Marshall, I;
Thrippleton, MJ;
Bastin, ME;
Mollison, D;
Dickie, DA;
Chappell, FM;
Semple, SIK;
... Chandran, S; + view all
(2018)
Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study.
Journal of Neurology
, 265
(8)
pp. 1795-1802.
10.1007/s00415-018-8903-y.
|
|
|
McNicholas, N;
Hutchinson, M;
McGuigan, C;
Chataway, J;
(2018)
2017 McDonald diagnostic criteria: A review of the evidence.
Multiple Sclerosis and Related Disorders
, 24
pp. 48-54.
10.1016/j.msard.2018.05.011.
(In press).
|
|
Mehta, AR;
Carpenter, JR;
Nicholas, JM;
Chataway, J;
Virgo, B;
Parmar, MKB;
Chandran, S;
(2023)
The role of placebo control in clinical trials for neurodegenerative diseases.
[Letter].
Nature Medicine
10.1038/d41591-023-00080-0.
|
|
Mehta, Arpan R;
Pal, Suvankar;
Chataway, Jeremy;
Carpenter, James R;
Parmar, Mahesh KB;
Chandran, Siddharthan;
(2022)
Smarter adaptive platform clinical trials in neurology: a showcase for UK innovation.
Brain
, 145
(8)
e64-e65.
10.1093/brain/awac169.
|
|
Middleton, RM;
Rodgers, WJ;
Chataway, J;
Schmierer, K;
Rog, D;
Galea, I;
Akbari, A;
... Ford, DV; + view all
(2018)
Validating the portal population of the United Kingdom Multiple Sclerosis Register.
Multiple Sclerosis and Related Disorders
, 24
pp. 3-10.
10.1016/j.msard.2018.05.015.
|
|
Monschein, T;
Hartung, HP;
Zrzavy, T;
Barnett, M;
Boxberger, N;
Berger, T;
Chataway, J;
... Zettl, UK; + view all
(2021)
Vaccination and multiple sclerosis in the era of the COVID-19 pandemic.
Journal of Neurology, Neurosurgery and Psychiatry
10.1136/jnnp-2021-326839.
(In press).
|
|
|
Motl, Robert W;
Sandroff, Brian M;
Hernandez, Roberto S;
Amato, Maria Pia;
Brichetto, Giampaolo;
Chataway, Jeremy;
Chiaravalloti, Nancy D;
... CogEx Research Team; + view all
(2024)
Heterogeneity of aerobic fitness changes with exercise training in progressive multiple sclerosis: Secondary, exploratory analysis of data from the CogEx trial.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
, 10
(4)
10.1177/20552173241301030.
|
|
|
Murphy, O;
Zandi, MS;
Lindenberg, N;
Murphy, E;
Chataway, J;
(2016)
Bone health in patients with multiple sclerosis relapses.
Multiple Sclerosis and Related Disorders
, 6
pp. 75-80.
10.1016/j.msard.2016.02.003.
|
|
Nicholas, Richard;
Tallantyre, Emma Clare;
Witts, James;
Marrie, Ruth Ann;
Craig, Elaine M;
Knowles, Sarah;
Pearson, Owen Rhys;
... Robertson, Neil; + view all
(2024)
Algorithmic approach to finding people with multiple sclerosis using routine healthcare data in Wales.
Journal of Neurology, Neurosurgery & Psychiatry
, 95
(11)
pp. 1032-1035.
10.1136/jnnp-2024-333532.
|
|
|
Nicholas, RS;
Han, E;
Raffel, J;
Chataway, J;
Friede, T;
(2019)
Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials.
Multiple Sclerosis Journal
, 25
(11)
pp. 1462-1471.
10.1177/1352458518794063.
|
|
|
O'Herlihy, F;
John, NA;
Li, V;
Porter, B;
Lyons, L;
Rakusa, M;
Curtis, C;
... Chataway, J; + view all
(2019)
Screening for urinary tract colonisation prior to corticosteroid administration in acute multiple sclerosis relapses: Validation of an updated algorithm.
[Rapid communication].
Journal of the Neurological Sciences
, 407
, Article 116456. 10.1016/j.jns.2019.116456.
|
|
O'Loughlin, E;
Hourihan, S;
Chataway, J;
Playford, ED;
Riazi, A;
(2017)
The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals.
Disability and Rehabilitation
, 39
(18)
pp. 1821-1828.
10.1080/09638288.2016.1211760.
|
|
|
Pal, Suvankar;
Chataway, Jeremy;
Swingler, Robert;
Macleod, Malcolm R;
Carragher, Neil O;
Hardingham, Giles;
Selvaraj, Bhuvaneish Thangaraj;
... MND SMART Investigators; + view all
(2024)
Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial.
The Lancet Neurology
10.1016/S1474-4422(24)00326-0.
(In press).
|
|
|
Palladino, R;
Chataway, J;
Majeed, A;
Marrie, RA;
(2021)
Interface of Multiple Sclerosis, Depression, Vascular Disease, and Mortality: A Population-Based Matched Cohort Study.
Neurology
, 97
(13)
e1322-e1333.
10.1212/WNL.0000000000012610.
|
|
Palladino, Raffaele;
Chataway, Jeremy;
Mathew, Mekha;
Majeed, Azeem;
Marrie, Ruth Ann;
(2024)
Trajectories and management of vascular risk following the diagnosis of multiple sclerosis: A population-based matched cohort study between 1987 and 2018 in England.
Multiple Sclerosis Journal
10.1177/13524585241287388.
(In press).
|
|
Palladino, Raffaele;
Marrie, Ruth Ann;
Majeed, Azeem;
Chataway, Jeremy;
(2023)
Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based study.
Multiple Sclerosis Journal
, 29
(6)
pp. 671-679.
10.1177/13524585231164296.
|
|
Palladino, R;
Marrie, RA;
Majeed, A;
Chataway, J;
(2020)
Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England.
JAMA Neurology
10.1001/jamaneurol.2020.0664.
(In press).
|
|
Phé, V;
Pakzad, M;
Curtis, C;
Porter, B;
Haslam, C;
Chataway, J;
Panicker, JN;
(2016)
Urinary tract infections in multiple sclerosis.
Multiple Sclerosis Journal
, 22
(7)
pp. 855-861.
10.1177/1352458516633903.
|
|
Phe, V;
Pakzad, M;
Haslam, C;
Gonzales, G;
Curtis, C;
Porter, B;
Chataway, J;
(2017)
Open label feasibility study evaluating D-mannose combined with home-based monitoring of suspected urinary tract infections in patients with multiple sclerosis.
Neurourology and Urodynamics
, 36
(7)
pp. 1770-1775.
10.1002/nau.23173.
|
|
|
Plantone, D;
De Angelis, F;
Doshi, A;
Chataway, J;
(2016)
Dimethyl fumarate may still have a role in progressive multiple sclerosis.
Therapeutic Advances in Neurological Disorders
, 9
(4)
pp. 344-345.
10.1177/1756285616640396.
|
|
Plantone, D;
De Angelis, F;
Doshi, A;
Chataway, J;
(2016)
Secondary Progressive Multiple Sclerosis: Definition and Measurement.
CNS Drugs
, 30
(6)
pp. 517-526.
10.1007/s40263-016-0340-9.
|
|
Porter, B;
John, NA;
Brenner, R;
Wilson, HC;
Turner, B;
Chataway, J;
(2019)
Urinary tract infection in multiple sclerosis: closing an audit loop by co-design and innovation.
British Journal of Neuroscience Nursing
, 15
(1)
10.12968/bjnn.2019.15.1.20.
|
|
Preziosa, Paolo;
Rocca, Maria A;
Pagani, Elisabetta;
Valsasina, Paola;
Amato, Maria Pia;
Brichetto, Giampaolo;
Bruschi, Nicolo;
... Filippi, Massimo; + view all
(2023)
Structural and functional magnetic resonance imaging correlates of fatigue and dual-task performance in progressive multiple sclerosis.
Journal of Neurology
, 270
pp. 1543-1563.
10.1007/s00415-022-11486-0.
|
   |
|
Rakusa, Martin;
Chataway, Jeremy;
Hardy, Todd A;
(2023)
The Impact of Relapses on Pain and Quality of Life in Patients with Multiple Sclerosis Treated with Corticosteroids.
Pharmaceuticals
, 16
(9)
, Article 1244. 10.3390/ph16091244.
|
|
|
Ramari, Cintia;
D'hooge, Mieke;
Dalgas, Ulrik;
Feinstein, Anthony;
Amato, Maria Pia;
Brichetto, Giampaolo;
Chataway, Jeremy;
... Feys, Peter; + view all
(2024)
Prevalence and Associated Clinical Characteristics of Walking-Related Motor, Cognitive, and Fatigability in Progressive Multiple Sclerosis: Baseline Results From the CogEx Study.
Neurorehabilitation and Neural Repair
, 38
(5)
pp. 327-338.
10.1177/15459683241236161.
|
|
Rocca, Maria A;
Valsasina, Paola;
Romano, Francesco;
Tedone, Nicolo;
Amato, Maria Pia;
Brichetto, Giampaolo;
Boccia, Vincenzo Daniele;
... Filippi, Massimo; + view all
(2024)
Cognitive rehabilitation effects on grey matter volume and Go-NoGo activity in progressive multiple sclerosis: results from the CogEx trial.
Journal of Neurology, Neurosurgery & Psychiatry
10.1136/jnnp-2024-333460.
(In press).
|
|
Rodgers, J;
Friede, T;
Vonberg, FW;
Constantinescu, CS;
Coles, A;
Chataway, J;
Duddy, M;
... MS Register group; + view all
(2022)
The impact of smoking cessation on multiple sclerosis disease progression.
Brain
, 145
(4)
pp. 1368-1378.
10.1093/brain/awab385.
|
|
Romano, Francesco;
Rocca, Maria A;
Pagani, Elisabetta;
Amato, Maria Pia;
Brichetto, Giampaolo;
Chataway, Jeremy;
Chiaravalloti, Nancy D;
... Filippi, Massimo; + view all
(2025)
Effects of cognitive rehabilitation and exercise on brain structure in progressive multiple sclerosis: results from the CogEx trial.
Journal of Neurology
, 272
, Article 645. 10.1007/s00415-025-13382-9.
|
|
|
Samani, A;
Davagnanam, I;
Cockerell, OC;
Ramsay, A;
Patani, R;
Chataway, J;
(2015)
Lymphomatosis Cerebri: a treatable cause of rapidly progressive dementia.
Journal of Neurology, Neurosurgery & Psychiatry
, 86
(2)
pp. 238-240.
10.1136/jnnp-2013-307327.
|
|
|
Sandroff, BM;
Motl, RW;
Amato, MP;
Brichetto, G;
Chataway, J;
Chiaravalloti, ND;
Cutter, GR;
... Feinstein, A; + view all
(2021)
Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study.
Multiple Sclerosis Journal
10.1177/13524585211048397.
(In press).
|
|
|
Scott, S;
Chataway, J;
Stone, J;
Smith, C;
Davenport, R;
(2016)
Clinicopathological case: rapid cognitive decline in an older man.
Practical Neurology
, 16
pp. 466-474.
10.1136/practneurol-2015-001322.
|
|
|
Solanky, BS;
John, NA;
DeAngelis, F;
Stutters, J;
Prados, F;
Schneider, T;
Parker, RA;
... MS-SMART Investigators, ./; + view all
(2020)
NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study.
American Journal of Neuroradiology
10.3174/ajnr.A6809.
(In press).
|
|
Sormani, Maria Pia;
Chataway, Jeremy;
Kent, David M;
Marrie, Ruth Ann;
(2023)
Assessing heterogeneity of treatment effect in multiple sclerosis trials.
Multiple Sclerosis Journal
, 29
(9)
pp. 1158-1161.
10.1177/13524585231189673.
|
|
Tudor, KI;
Eames, S;
Haslam, C;
Chataway, J;
Liechti, MD;
Panicker, JN;
(2018)
Identifying barriers to help-seeking for sexual dysfunction in multiple sclerosis.
Journal of Neurology
10.1007/s00415-018-9064-8.
(In press).
|
|
Tur, C;
Grussu, F;
De Angelis, F;
Prados, F;
Kanber, B;
Calvi, A;
Eshaghi, A;
... Gandini Wheeler-Kingshott, CAM; + view all
(2021)
Spatial patterns of brain lesions assessed through covariance estimations of lesional voxels in multiple Sclerosis: The SPACE-MS technique.
NeuroImage: Clinical
, 33
, Article 102904. 10.1016/j.nicl.2021.102904.
|
|
|
Tur, C;
Moccia, M;
Barkhof, F;
Chataway, J;
Sastre-Garriga, J;
Thompson, AJ;
Ciccarelli, O;
(2018)
Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting.
Nature Reviews Neurology
, 14
pp. 75-93.
10.1038/nrneurol.2017.171.
|
|
Veldkamp, R;
D'hooge, M;
Sandroff, BM;
DeLuca, J;
Kos, D;
Salter, A;
Feinstein, A;
... CogEx, Res Team; + view all
(2023)
Profiling cognitive–motor interference in a large sample of persons with progressive multiple sclerosis and impaired processing speed: results from the CogEx study.
Journal of Neurology
, 270
pp. 3120-3128.
10.1007/s00415-023-11636-y.
|
|
Wade, Charles;
Doshi, Anisha;
Mangion, Sean Apap;
Williams, Tom;
Bianchi, Alessia;
De Angelis, Floriana;
Wright, Sarah;
... The UCL MS-STAT2 Investigators, .; + view all
(2025)
Executive Dysfunction and Disability in SPMS: Predictive
Value of the Frontal Assessment Battery in the UCLH
MS-STAT2 Cohort.
European Journal of Neurology
, 32
(7)
, Article e70286. 10.1111/ene.70286.
|
|
|
Wade, Charles;
Runeckles, Kyle;
Chataway, Jeremy;
Houlden, Henry;
Lynch, David S;
(2024)
CSF1R-Related Disorder: Prevalence of CSF1R Variants and Their Clinical Significance in the UK Population.
Neurology Genetics
, 10
(4)
, Article e200179. 10.1212/NXG.0000000000200179.
|
|
|
Wade, Charles;
Williams, Thomas;
Labrum, Robyn;
Patel, Yogen;
Cali, Elisa;
Davagnanam, Indran;
Adams, Matthew E;
... Lynch, David S; + view all
(2023)
Leukoencephalopathy caused by a 17p13.3 microdeletion.
Journal of Neurology, Neurosurgery & Psychiatry
10.1136/jnnp-2023-331986.
(In press).
|
|
|
Webb, Edward JD;
Meads, David;
Eskyte, Ieva;
Ford, Helen L;
Bekker, Hilary L;
Chataway, Jeremy;
Pepper, George;
... Manzano, Ana; + view all
(2023)
Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices.
The Patient - Patient-Centered Outcomes Research
, 16
pp. 457-471.
10.1007/s40271-023-00622-1.
|
|
Webb, EJD;
Meads, D;
Eskyte, I;
King, N;
Dracup, N;
Chataway, J;
Ford, HL;
... Manzano, A; + view all
(2018)
A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis.
The Patient - Patient-Centered Outcomes Research
, 11
(4)
pp. 391-402.
10.1007/s40271-017-0296-y.
|
|
Webb, EJD;
Meads, DM;
Eskyte, I;
Ford, HL;
Bekker, HL;
Chataway, J;
Pepper, G;
... Manzano, A; + view all
(2020)
The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.
The Patient - Patient-Centered Outcomes Research
, 13
(5)
pp. 583-597.
10.1007/s40271-020-00429-4.
|
|
Williams, T;
John, N;
Calvi, A;
Bianchi, A;
De Angelis, F;
Doshi, A;
Wright, S;
... Beveridge, J; + view all
(2024)
Investigating the relationship between thalamic iron concentration and disease severity in secondary progressive multiple sclerosis using quantitative susceptibility mapping: Cross-sectional analysis from the MS-STAT2 randomised controlled trial.
NeuroImage: Reports
, 4
(3)
, Article 100216. 10.1016/j.ynirp.2024.100216.
|
|
Williams, T;
Zetterberg, H;
Chataway, J;
(2021)
Serum Neurofilament Light concentrations are not associated with renal function in secondary progressive multiple sclerosis.
Biomarkers in Neuropsychiatry
, 5
, Article 100044. 10.1016/j.bionps.2021.100044.
|
|
|
Williams, TE;
Holdsworth, KP;
Nicholas, JM;
Eshaghi, A;
Katsanouli, T;
Wellington, H;
Heslegrave, A;
... Chataway, J; + view all
(2022)
Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis: From the MS-STAT Randomized Controlled Trial.
Neurology, Neuroimmunology and Neuroinflammation
, 9
(2)
, Article e1130. 10.1212/NXI.0000000000001130.
|
|
|
Williams, Thomas;
Chataway, Jeremy;
(2022)
Beyond ocrelizumab in primary progressive multiple sclerosis.
Nature Reviews Neurology
, 18
pp. 641-642.
10.1038/s41582-022-00724-8.
|
|
Williams, Thomas;
John, Nevin;
Doshi, Anisha;
Chataway, Jeremy;
(2024)
Adult inflammatory leukoencephalopathies.
Handbook of Clinical Neurology
, 204
pp. 399-430.
10.1016/B978-0-323-99209-1.00003-X.
|
|
Williams, Thomas;
Lange, Frederic;
Smith, Kenneth J;
Tachtsidis, Ilias;
Chataway, Jeremy;
(2024)
Investigating cortical hypoxia in multiple sclerosis via time-domain near-infrared spectroscopy.
Annals of Clinical and Translational Neurology
10.1002/acn3.52150.
(In press).
|
|
Williams, T;
Chataway, J;
(2019)
Immune-mediated encephalitis with daclizumab: The final nail.
[Letter].
Multiple Sclerosis Journal
, 25
(5)
10.1177/1352458518791374.
|
|
|
Williams, T;
Houlden, H;
Murphy, E;
John, N;
Fox, NC;
Schott, JM;
Adams, M;
... Lynch, DS; + view all
(2020)
How to diagnose difficult white matter disorders.
Practical Neurology
10.1136/practneurol-2020-002530.
(In press).
|
|
|
Williams, T;
Zetterberg, H;
Chataway, J;
(2020)
Neurofilaments in progressive multiple sclerosis: a systematic review.
Journal of Neurology
10.1007/s00415-020-09917-x.
(In press).
|
|
|
Wong, C;
Stavrou, M;
Elliott, E;
Gregory, JM;
Leigh, N;
Pinto, AA;
Williams, TL;
... Chandran, S; + view all
(2021)
Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective.
Brain Communications
, 3
(4)
, Article fcab242. 10.1093/braincomms/fcab242.
|
|
|
Wong, Charis;
Dakin, Rachel S;
Williamson, Jill;
Newton, Judith;
Steven, Michelle;
Colville, Shuna;
Stavrou, Maria;
... Chandran, Siddharthan; + view all
(2022)
Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease.
BMJ Open
, 12
(7)
, Article e064173. 10.1136/bmjopen-2022-064173.
|
|
Wong, Charis;
Gregory, Jenna M;
Liao, Jing;
Egan, Kieren;
Vesterinen, Hanna M;
Ahmad Khan, Aimal;
Anwar, Maarij;
... Macleod, Malcolm; + view all
(2023)
Systematic, comprehensive, evidence-based approach to identify neuroprotective interventions for motor neuron disease: using systematic reviews to inform expert consensus.
BMJ Open
, 13
(2)
, Article e064169. 10.1136/bmjopen-2022-064169.
|
|
Ziemssen, Tjalf;
Bhan, Virender;
Chataway, Jeremy;
Chitnis, Tanuja;
Campbell Cree, Bruce Anthony;
Havrdova, Eva Kubala;
Kappos, Ludwig;
... Hach, Thomas; + view all
(2023)
Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies.
Neurology, Neuroimmunology & Neuroinflammation
, 10
(1)
, Article e200064. 10.1212/NXI.0000000000200064.
|
|
Zirra, A;
Bointon, E;
Chataway, J;
Porter, B;
(2017)
Timely relapse treatment in multiple sclerosis: health utility analysis of the NeuroDirect integrated pathway.
British Journal of Neuroscience Nursing
, 13
(4)
pp. 70-77.
10.12968/bjnn.2017.13.4.160.
|
Proceedings paper
|
Lange, F;
Williams, T;
Chataway, J;
Smith, KJ;
Tachtsidis, I;
(2021)
Cerebral time domain near-infrared spectroscopy of people with multiple sclerosis: A feasibility study.
In:
Proceedings of SPIE: Diffuse Optical Spectroscopy and Imaging VIII.
SPIE
|
|
|
Lange, F;
Williams, T;
Chataway, J;
Smith, KJ;
Tachtsidis, I;
(2021)
Cerebral time domain near-infrared spectroscopy of people with multiple sclerosis: A feasibility study.
In:
European Conferences on Biomedical Optics 2021 (ECBO).
(pp. ETu3C.6).
Optical Society of America (OSA): Munich, Germany.
|
Working / discussion paper
|
Coleman, Annabelle;
Touzé, Alexiane;
Farag, Mena;
Pengo, Marta;
Murphy, Michael J;
Hassan, Yara;
Thackeray, Olivia;
... Byrne, Lauren M; + view all
(2023)
Validation of remote collection and quantification of blood Neurofilament light in neurological diseases.
MedRxiv: Cold Spring Harbor, NY, USA.
|
Conference item
|
Allen, C;
Fernandes, L;
Williams, T;
Evangelou, N;
Chataway, J;
Tallantyre, E;
Ford, H;
(2021)
A multicentre audit of the use of MRI in multiple sclerosis.
Presented at: ECTRIMS 2021.
|
|
Chan, D;
Binks, S;
Nicholas, J;
Alsanousi, A;
Fox, N;
Wilkie, D;
Nicholas, R;
(2016)
Effect of high-dose simvastatin on cognition in secondary progressive multiple sclerosis (MS-STAT cognitive): a randomised, placebo-controlled, phase 2 trial.
Presented at: 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), London, UK.
|
|
|
Chataway, J;
(2021)
Future treatment options for progressive MS.
Presented at: ECTRIMS 2021.
|
|
Chataway, J;
(2019)
155 How to design RCTs for SPMS.
Presented at: 35th Congress of the European Committee for Treatment and Research of Multiple Sclerosis, Stockholm, Sweden.
|
|
|
Chataway, J;
(2016)
Unblocking the bottleneck - better trial design in progressive multiple sclerosis.
Presented at: 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), London, UK.
|
|
Chataway, J;
Chandran, S;
Miller, D;
Connick, P;
Giovannoni, G;
Pavitt, S;
Stallard, N;
... Sharrack, B; + view all
(2016)
Recruitment In Multiple Sclerosis Trials: The MS-SMART Experience.
Presented at: 2016 Annual Meeting of the Association of British Neurologists (ABN), Brighton, UK.
|
|
Chataway, J;
Chandran, S;
Miller, D;
Connick, P;
Giovannoni, G;
Pavitt, S;
Stallard, N;
... Plantone, D; + view all
(2016)
THE MS-Smart Trial In Secondary Progressive MS - Current Update.
Presented at: 2016 Annual Meeting of the Association of British Neurologists (ABN), Brighton, UK.
|
|
|
Doshi, A;
Castellazzi, G;
Muhlert, N;
Alahmadi, A;
Prados, F;
Wheeler-Kingshott, C;
Ciccarelli, O;
(2019)
180 Cognitive diagnostic criteria lead to distinct patterns of functional connectivity in secondary progressive MS.
Presented at: Annual Meeting of the Association-of-British-Neurologists (ABN), Edinburgh, Scotland.
|
|
|
Li, V;
Porter, B;
Curtis, C;
Panicker, J;
Pakzad, M;
Chataway, J;
(2019)
P424 Patients with multiple sclerosis with recurrent emergency attendances and hospital admissions for urinary tract infections.
Presented at: 35th Congress of the European Committee for Treatment and Research of Multiple Sclerosis, Stockholm, Sweden.
|
|
|
Monteverdi, A;
Solanky, B;
De Angelis, F;
Plantone, D;
Stutters, J;
John, N;
Casiraghi, L;
... MS-SMART trialists; + view all
(2018)
Exploring metabolite profiling of patients with secondary progressive multiple sclerosis.
Presented at: ISMRM 2018, Paris, France.
|
|
|
Paling, D;
Angelini, L;
Mazza, C;
Angelis, FD;
Brittain, G;
Buckley, E;
Nair, S;
... Chataway, J; + view all
(2021)
Deep grey matter atrophy predicts longitudinal worsening of gait dynamics in progressive MS; a gait biosensor subgroup analysis of the MS-SMART clinical trial [NCT01910259].
Presented at: ECTRIMS 2021.
|
|
|
Palladino, R;
Marrie, RA;
Majeed, A;
Chataway, J;
(2021)
Management of vascular risk in people with multiple sclerosis in England: a population-based matched cohort study.
Presented at: UNSPECIFIED.
|
|
Palladino, R;
Marrie, RA;
Majeed, A;
Chataway, J;
(2019)
82 Evaluating the risk of macrovascular events and mortality in individuals with multiple sclerosis in England: a population-based nested case-control study.
Presented at: 35th Congress of the European Committee for Treatment and Research of Multiple Sclerosis, Stockholm, Sweden.
|
|
|
Preziosa, P;
Rocca, M;
Amato, M;
Brichetto, G;
Chataway, J;
Chiaravalloti, N;
Cutter, G;
... Filippi, M; + view all
(2022)
Frontal cortico-subcortical MRI correlates of fatigue and dual-task performance in progressive multiple sclerosis.
Presented at: 8th Congress of the European Academy of Neurology, Vienna, Austria.
|
|
Sturrock, A;
Chataway, J;
Teare, L;
(2017)
PO186 Hereditary leukoencephalopathy (hls) and csf1r heterogeneity.
Presented at: Association of British Neurologists (ABN) Annual Meeting, Liverpool, UK.
|
|
Poster
|
Connick, P;
Miller, D;
Pavitt, S;
Giovannoni, G;
Wheeler-Kingshott, C;
Weir, C;
Stallard, N;
... The MS-SMART Trialists; + view all
(2016)
MS-SMART trial design and recruitment status: a multi-arm phase IIB randomised double blind placebo-controlled clinical trial comparing the efficacy of three repositioned neuroprotective drugs in secondary progressive multiple sclerosis.
Presented at: 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), London, UK.
|
|
|
De Angelis, F;
Cameron, J;
Connick, P;
Miller, DH;
Pavitt, S;
Giovannoni, G;
Wheeler-Kingshott, C;
... for MS-SMART trialists; + view all
(2016)
Optical coherence tomography in secondary progressive multiple sclerosis: a baseline data report from the MS-SMART trial.
Presented at: 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), London, UK.
|
|
Plantone, D;
Solanky, B;
Pavitt, S;
Giovannoni, G;
Wheeler-Kingshott, C;
De Angelis, F;
Doshi, A;
... for the MS SMART trialists; + view all
(2016)
Initial cross-sectional MR spectroscopy analysis of a cohort of secondary progressive MS patients enrolled in the MS-SMART trial.
Presented at: 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), London, UK.
|
